Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-TKI Resistant Mutation”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Large-scale testing (Phase 3)UnknownNCT02972333
What this trial is testing

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Who this might be right for
EGFR-TKI Resistant MutationNonsmall Cell Lung CancerAZD9291+1 more
Shandong Cancer Hospital and Institute 150
Not applicableLooking for participantsNCT05598528
What this trial is testing

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Who this might be right for
Lung Cancer, Non-small CellEGFR Gene MutationEGFR-TKI Resistant Mutation+2 more
Second Xiangya Hospital of Central South University 210
Testing effectiveness (Phase 2)UnknownNCT04405674
What this trial is testing

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Chest Hospital 120
Not applicableStudy completedNCT03059641
What this trial is testing

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

Who this might be right for
Lung NeoplasmsLung Cancer, Nonsmall CellAdenocarcinoma of Lung+1 more
Geneplus-Beijing Co. Ltd. 300
Not applicableWithdrawnNCT02368990
What this trial is testing

T790M Mutation Positive 2nd Line STandard of cAre Registry

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca
Not applicableLooking for participantsNCT01994057
What this trial is testing

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)EGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation+2 more
Sun Yat-sen University 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT06363734
What this trial is testing

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Who this might be right for
Non-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more
Tianjin Medical University Cancer Institute and Hospital 32
Not applicableUnknownNCT01776684
What this trial is testing

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Who this might be right for
EGFR Mutation Positive Non-small Cell Lung Cancer
Samsung Medical Center 200
Testing effectiveness (Phase 2)Study completedNCT01580735
What this trial is testing

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Kyowa Kirin Co., Ltd. 40
Large-scale testing (Phase 3)Study completedNCT03515837
What this trial is testing

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 492
Testing effectiveness (Phase 2)Study completedNCT01982955
What this trial is testing

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Who this might be right for
Non-small Cell Lung Cancer
Merck KGaA, Darmstadt, Germany 88
Testing effectiveness (Phase 2)Looking for participantsNCT06706076
What this trial is testing

BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics 266
Early research (Phase 1)Ended earlyNCT02468661
What this trial is testing

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 23
Not applicableStudy completedNCT02575560
What this trial is testing

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
EGFR-TKI Resistant Mutation
Qingdao Central Hospital 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05256290
What this trial is testing

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Who this might be right for
Non-Small Cell Lung CancerAdvanced Non-Small Cell Squamous Lung CancerMetastatic Lung Non-Small Cell Carcinoma+7 more
Black Diamond Therapeutics, Inc. 200
Testing effectiveness (Phase 2)UnknownNCT02098954
What this trial is testing

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Who this might be right for
Carcinoma, Non-Small Cell LungEGFR Gene Mutation
Hunan Province Tumor Hospital 40
Not applicableUnknownNCT02661009
What this trial is testing

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

Who this might be right for
Non Small Cell Lung CancerEGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation
GenoSaber 1,000
Testing effectiveness (Phase 2)UnknownNCT05498389
What this trial is testing

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+6 more
Shanghai EpimAb Biotherapeutics Co., Ltd. 115
Large-scale testing (Phase 3)Ended earlyNCT02178397
What this trial is testing

Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR

Who this might be right for
NSCLC Patients With EGFR Activating Mutation
Centre Francois Baclesse 6
Early research (Phase 1)Not Yet RecruitingNCT07461727
What this trial is testing

An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases

Who this might be right for
Non-Small Cell Lung CancerMetastatic Non-small Cell Lung CancerLiver Metastases+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 15
Load More Results